Form 10-Q Ovid Therapeutics Inc. For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BTIG Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)
August 14, 2024 6:13 AM EDTBTIG analyst Thomas Shrader reiterated a Buy rating and $5.00 price target on Ovid Therapeutics Inc (NASDAQ: OVID).
The analyst comments "The P2 trial for OV888 in CCM is expected to start in 2H24 and could rapidly establish POC. The lesions (complex blood vessel tangles) are clearly visible in patients and treatment with OV888 has the chance to resolve them (not certain but seen in animal models). Similarly, OV329 is a safer Vigabatrin by design, so confirming safety in humans is highly de-risking, we believe. We hosted OVID management at the recent BTIG... More
